Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Shukra Pharmaceuticals has submitted its 32nd Annual Report for the financial year ended March 31, 2025 to BSE as required under Regulation 34 of the SEBI Listing Regulations. The 32nd AGM is scheduled for September 30, 2025 at 1:00 PM, to be held via video conferencing. Key agenda items include adoption of audited financials, declaration of a final dividend of 1% (Rs. 0.01 per equity share of Rs. 10 face value), re-appointment of Mr. Dhruvin Shah as Executive Director (rotational), and appointment of M/s Shah Sanghvi and Associates as new Statutory Auditor for a 5-year term (till 37th AGM in 2030), replacing the outgoing auditor M/s Maak & Associates. Mrs. Rupal Patel is proposed as Secretarial Auditor for 5 years from FY 2025-26. The Board fixed Saturday, September 13, 2025 as the record date for dividend eligibility.
This is a routine annual compliance filing. The tiny 1% dividend signals the company is profitable enough to pay shareholders, but the payout is negligible. The auditor rotation is procedural and should not impact the stock.